Clinical Trials Logo

Filter by:
NCT ID: NCT05821504 Completed - Healthy Clinical Trials

High-Intensity Interval Training and Performance

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The goal of this clinical trial was to compare to different types of high-intensity interval training in young, healthy females. The main questions were: Will changes in body composition differ between the two interventions? Will changes in endurance and muscle performance differ between the two interventions? Participants were randomized to 8 weeks of high-intensity interval training involving body weight, plyometric exercises or cycling only. Researchers compared changes in endurance performance, body composition, and muscle performance to determine if there were differences between groups.

NCT ID: NCT05821153 Completed - Alzheimer Disease Clinical Trials

Low Dose IL2 Immunotherapy in AD

Start date: June 19, 2019
Phase: Phase 1
Study type: Interventional

Neuroinflammation is a significant component of Alzheimer disease (AD). Our data demonstrated compromised regulatory T cells (Tregs) phenotype and suppressive function in AD patients, skewing the immune system toward a proinflammatory status and potentially contributing in disease progression. Low dose interleukin-2 (IL-2) is now viewed as a very promising immunoregulatory drug having the capacity to selectively expand and restore functional Tregs. This study is a phase I open-label study to assess subcutaneous interleukin-2 (IL2) safety and potential efficacy as a Treg inducer in AD. 8 Alzheimer dementia patients with mild clinical dementia will be recruited into the study. The baseline cognitive status will be evaluated in these patients. Monthly five-day-courses of subcutaneous IL2 (1MUI/day) will be administered for a total of 4 months. Changes in Tregs from pre to post injections will be measured during the study period. The expected time participants will be in the study is 6 months.

NCT ID: NCT05821023 Completed - Clinical trials for Breast Cancer Screening

Messaging Strategies to Reduce Breast Cancer Over-screening in Older Women

Start date: May 12, 2023
Phase: N/A
Study type: Interventional

This is an online survey experiment with data collection over 2 time points two weeks apart. This is Aim 2 of a three-aim R01 project; overall project goal is to better understand how messages from different sources interact to affect older women's breast cancer screening decisions. In this current project, the investigators propose to test the effect of combined exposure to a clinician message + a message from another source (i.e. family/friend or media) on older women's breast cancer screening beliefs, attitudes, and intentions.

NCT ID: NCT05820971 Completed - Clinical trials for Adequate Reporting in Randomized Controlled Trials

A Short CONSORT Checklist for Peer Reviewers to Improve the Reporting of Randomised Controlled Trials Published

CONSORT-PR
Start date: June 15, 2019
Phase: N/A
Study type: Interventional

Transparent and accurate reporting is key, so that readers can adequately interpreting the results of a study. Despite improvement with implementation of the CONSORT Statement (CONsolidated Standards for Reporting Trials), there remain major reporting deficiencies in published randomized controlled trials (RCT). The aim of this project is to evaluate whether reminding peer reviewers of the most important CONSORT items (including a short explanation of those items) will result in higher adherence to CONSORT guidelines in published RCTs. During the standard peer-review process, peer-reviewers will be randomly allocated to use either (i) a short version of the CONSORT checklist including the ten most important and poorly reported CONSORT items as defined by a group of experts of the CONSORT Statement (C-short); or (ii) no checklist. The aim is to find an intervention which improves the reporting, making it easier for readers to adequately interpret the presented results.

NCT ID: NCT05820399 Completed - Exercise Training Clinical Trials

Guayusa Extract on Exercise Training

Start date: September 5, 2022
Phase: N/A
Study type: Interventional

Guayusa extract is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (~20% caffeine, 30% chlorogenic acids, 5% catechins). It is also remarkably low in tannins which are responsible for the bitter taste found in most teas - giving it a sweet flavor profile. As such, it is marketed as an ingredient that can help support energy and performance with potential health-related benefits due to its antioxidant properties. Indeed, ingredients such as these are often consumed by individuals prior to exercise in order to help improve exercise performance, or otherwise to support health-related goals. Whereas several studies have suggested that caffeine and chlorogenic acid consumption may improve performance, mood, and concentration, and some evidence in animals have linked catechin consumption to improved health outcomes, no studies have previous studied whether guayusa extract supplementation helps to support exercise performance in humans. In this study, we will test the whether dietary supplementation with the botanical organic guayusa extract helps support (1) the desire to exercise and exercise performance throughout a 6-week high intensity exercise training program, and thus (2) helps support the physiological adaptations (including body composition, fasting metabolic biomarkers, blood pressure and heart rate, submaximal and maximal exercise performance and fuel metabolism, and changes in the gut microbiome/mycobiome) to a 6-week high intensity exercise training program. Question 1: Does organic guayusa extract supplementation support the desire to train and training load in physically-active women performing a high-intensity exercise training program? Question 2: Does organic guayusa extract supplementation support physiological adaptation to exercise (including body composition, fasting metabolic biomarkers, blood pressure and heart rate, submaximal and maximal exercise performance and fuel metabolism, and changes in the gut microbiome/mycobiome) in physically-active women performing a high-intensity exercise training program?

NCT ID: NCT05820308 Completed - Depression Clinical Trials

Companion Dog Walking for ICU Survivor Health

POOCH
Start date: May 15, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to determine the feasibility and acceptability of a randomized controlled trial comparing a pet dog walking intervention to an attention control education intervention in adult intensive care unit survivors. The main question[s] it aims to answer are: - What is the feasibility of a pet dog-walking intervention compared to an attention control education intervention on depression, anxiety, cortisol, and quality of life for adult ICU survivors. - What is the acceptability of a pet dog-walking intervention compared to an attention control education intervention on depression, anxiety, cortisol, and quality of life for adult ICU survivors. The secondary question[s] it aims to answer are: - What are the differences in depression, anxiety, serum cortisol, and quality of life between and within a companion dog walking intervention compared to an attention control education intervention for ICU survivors? Participants in the intervention group will be asked to: - Participate in dog walking with their pet dog at least three times per week, for at least 10 minutes each walk, for 8-weeks. - Wear an activity monitor and record their dog walks in a diary. - Complete surveys to measure depression, anxiety, and quality of life at the start of the study, after week 4, and after week 8. - Have blood drawn to measure cortisol levels at the start of the study, after week 4, and after week 8. Participants in the control group will be asked to: - Read educational materials about their pet dog's health once every week (education materials are provided by the researchers). - Wear an activity monitor and record when they read their education materials in a diary. - Complete surveys to measure depression, anxiety, and quality of life at the start of the study, after week 4, and after week 8. - Have blood drawn to measure cortisol levels at the start of the study, after week 4, and after week 8. Participants will be assigned to an intervention group or a control group to see if there are differences in depression, anxiety, serum cortisol, and quality of life.

NCT ID: NCT05820139 Completed - Voiding Dysfunction Clinical Trials

Evaluating the Optimal Volume Voided for Passage of a Backfill-Assisted Voiding Trial Following Urogynecologic Surgery

Start date: July 11, 2023
Phase: N/A
Study type: Interventional

Urinary retention can lead to bladder over-distention, ischemia, and long-term voiding dysfunction, and early identification of urinary retention can help prevent these adverse events

NCT ID: NCT05820100 Completed - Clinical trials for Retinitis Pigmentosa

Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

Start date: April 25, 2023
Phase:
Study type: Observational

This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT and MLSDT at multiple luminance levels and (ii) reliability and content validity of MLYMT and MLSDT.

NCT ID: NCT05819424 Completed - Immune Surveillance Clinical Trials

EpiCor Clinical Study on Rapid Immune Modulating Effects

Start date: May 16, 2023
Phase: N/A
Study type: Interventional

Clinical verification study evaluating the effects of a nutraceutical product. This study involves thirty participants composed of healthy adults, who will be taking either a placebo or nutraceutical supplement at different times. Testing for immune status, cytokine levels, and immune responsiveness will be conducted to determine the acute impact of the nutraceutical on immune function compared to a placebo.

NCT ID: NCT05819086 Completed - Smoking Cessation Clinical Trials

Message Testing in Aging African American Smokers

MCAAAS-2
Start date: March 13, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to examine different messages to motivate smokers who self-identify as an African American current smoker, between the ages of 50-80 years old to quit smoking. Participants will be asked to complete a survey and look at two messages.